SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

A rebound in biotech stocks is driving LABU higher, with traders tracking the sectors move through XBI and positioning around upcoming inflation data that could affect rate-sensitive biotech shares. The community is split between expecting the bounce to continue and cautioning that LABUs 3x leverage can magnify pullbacks.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires quarterly results and stepped-up share repurchases are driving discussion: some traders view the buybacks as a vote of confidence from Greg Abel, while others focus on weaker insurance performance and question whether repurchases can continue.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is drawing attention as traders question whether enterprise AI projects will translate into sustained consulting revenue or instead reduce billable work and pressure margins. The debate is playing out against a sharp rally and technical resistance, with bearish traders watching for a pullback and bulls pointing to insider buying and continued demand for AI implementation.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Foxs acquisition of Roku has closed, ending ROKUs run as a standalone Nasdaq-listed company and shifting holders into the deals cash-and-Fox-stock consideration. The community is marking the end of the ticker with a mix of congratulations and disappointment that the sale capped Rokus potential, while some traders are also discussing bullish call activity.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs persistent selloff and underperformance dominate discussion, with traders warning of further losses while others treat the decline as a buying opportunity. Bulls point to Stellars tokenization and institutional-adoption prospects, including DTCC-related plans, but skeptics argue that partnerships have not translated into token demand and question the tokenomics.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines strong initial RASONQUE launch and better-than-expected quarterly results are driving attention, alongside analyst upgrades and expectations for further growth. Traders are debating whether the early sales pace can persist amid high spending, while the pending European decision and first-line trial remain potential catalysts.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

A Nasdaq and technology-sector selloff is weighing on JEPQ, prompting traders to compare its decline with the broader tech pullback. Many are buying the dip for monthly income, while others question whether distributions offset the funds price weakness and limited upside from its covered-call strategy.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Attention centers on long-term lorundrostat data reporting that blood-pressure benefits persisted for two years after treatment ended, alongside the upcoming FDA decision on the hypertension drug. Traders view the durability findings as encouraging but remain divided amid the stocks weakness and the binary regulatory catalyst.

NRG Energy, Inc. engages in the production, sale, and distribution of energy and energy services. It operates through the following segments: Texas, East, West/Services/Other, Vivint Smart Home, and Corporate Activities. The Texas segment includes all activities related to customer, plant and market operations in Texas, other than Cottonwood. The East segment engages in all activities related to customer, plant and market operations in the East. The West/Services/Other segment is focused on all activities related to customer, plant and market operations in the West and Canada, and activities related to the Cottonwood facility and other investments. The Vivint Smart Home segment is a smart home platform that provides customers with technology, products and services to create a smarter, greener, safer home. The company was founded in 1989 and is headquartered in Houston, TX.

NRG Energy Inc.

NRG is drawing attention after a sharp rebound amid a prolonged selloff that traders have linked to weakness in AI-related power stocks and doubts about data-center demand. The community is divided between dip-buyers who see the AI electricity-demand thesis as intact and bears concerned that uncertain demand, power prices and customer rate pressures could undermine the growth story; options activity also reflects expectations of volatility.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus is drawing attention for the potential of its ITK inhibitor soquelitinib across several clinical indications, with traders watching for trial updates and possible partnerships. Optimists point to the science and reported institutional or insider buying, while skeptics focus on delayed data, the long path to revenue, and persistent short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stock Market Today: Dow Jones, S&P 500 Futures Trade Mixed Ahead of October's Jobs Report Airbnb, Cloudflare, Lam Research in Focus

U.S. stocks were mixed on Friday, with the Dow Jones, S&P 500, and Nasdaq 100 index futures moving in different directions.read more...

Lam Research Authorized To Repurchase $25 Bln Of Shares

(RTTNews) - Lam Research Corporation (LRCX), a provider of wafer-fabrication equipment and related services to the semiconductor makers, said that its board approved a $25 billion share repurchase drive and a quarterly dividend of $0.33 per share...

Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend

Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly DividendPR NewswireFREMONT, Calif., Nov. 5, 2026 FREMONT, Calif., Nov. 5, 2026...

Two Days Before Today's Selloff, Data Put Global September Chip Sales Up 146.8% Year to Year

Two Days Before Today's Selloff, Data Put Global September Chip Sales Up 146.8% Year to Year Two Days Before Today's Selloff, Data Put Global September Chip Sales Up 146.8% Year to YearPR NewswireSAN FRANCISCO, Nov. 5, 2026 SAN FRANCISCO, Nov. 5, 2026 /PRNewswire/ -- Equity Insider News Commentary...

AMAT Shares Plunge 30% in a Month: Should You Buy, Sell or Hold?

Applied Materials' stock declines amid semiconductor industry concerns, but AI-driven equipment demand and advanced packaging growth are tailwinds.

What Is Going on With Lam Research Stock on Tuesday?

Lam Research stock gained over 2.5% to $233 as record AI chip demand, strong guidance, and Jim Cramer's endorsement offset component bottlenecks and China headwinds.read more...

Jim Cramer Likes This Industrial Stock: 'It's Come Down A Great Deal'

Cramer recommends Howmet and J&J, prefers Micron over Western Digital, criticizes Nebius, and favors Lam Research over KLA.read more...

What UCTT's Q3 Beat and Strong Q4 Guidance Mean for Investors Now

Ultra Clean's strong Q3 earnings beat and upbeat Q4 outlook signal AI-driven semiconductor growth, but expansion costs and cash flow challenges remain key risks.

Is UCTT Worth Buying as Growth Accelerates but Cash Flow Weakens?

UCTT's surging earnings, rising semiconductor demand and improving margins support growth, but weak cash conversion and customer concentration pose risks.

UCTT Fell 31.6% in the Past Month: Is the Sell-Off an Opportunity?

UCTT shares plunged 31.6% in four weeks despite surging earnings and rising estimates, as strong semiconductor demand faces cash flow and dilution risks.

• Reported GAAP EPS of $2.20 up 74.60% YoY
• Reported revenue of $8.22B up 54.38% YoY

Lam Research faces China export-license restrictions that have limited its market, competition amid rapid technology change, and revenue variability because sales depend on a limited number of large customers.

Lam Research reported higher systems revenue on semiconductor demand in memory and non-memory markets, improved gross margin with favorable mix, and AI-related wafer-fabrication investment across memory and non-memory segments.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

LRCX Stock Sinks As Analysts Trim Targets, See Supply Constraints – But Longer-Term Bull Case Remains

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Lam Research reported record quarterly revenue of $8.22 billion and adjusted EPS of $2.20, both ahead of Street estimates.</li><li>BofA said Lam's December-quarter outlook would have been stronger without industry supply constraints.</li><li>Needham flagged an unexpected slowdown despite strong demand from China and NAND memory customers.</li></ul>Lam Research Corp. (LRCX) shares tumbled more than 8% in Thursday's premarket trading as multiple firms lowered their price targets following the semiconductor equipment maker's latest earnings report,&nbsp;The cuts followed better-than-expected fiscal first-quarter (Q1) results on Wednesday, although analysts maintained positive ratings despite the company's December-quarter outlook offering limited upside to expectations.As of this writing, <a href="https://stocktwits.com/symbol/LRCX">LRCX stock</a> was down over 8% and was among trending tickers on Stocktwits.<h2 class="st-heading-2">Analysts See Supply Constraints Limiting Near-Term Growth</h2>BofA argued that Lam was "supply constrained, not demand constrained," according to The Fly.&nbsp;The firm noted that September-quarter revenue and pro forma earnings per share were each 1% above Wall Street forecasts, while December-quarter guidance would have been higher without industry supply constraints.Needham similarly cited supply bottlenecks behind an unexpected deceleration in the December quarter. The firm said strength in China and NAND memory drove Lam's September-quarter revenue and gross margin above estimates.<h2 class="st-heading-2">MS Flags Expectations Reset, Citi Sees 2027 Outperformance</h2>Morgan Stanley called the December-quarter expectations miss "undoubtedly a negative," but said the earnings report represented an important reset in expectations for semiconductor production equipment.Citi analyst Atif Malik attributed his target reduction to lower market valuation multiples but maintained his expectation that Lam would outperform the broader wafer fabrication equipment market in 2027.<div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col><col><col></colgroup><tbody><tr><td>Firm</td><td>Rating</td><td>Previous Target</td><td>New Target</td><td>Change Vs. Last Close</td></tr><tr><td>Citi</td><td>Buy</td><td>$450</td><td>$435</td><td>+66.8%</td></tr><tr><td>Mizuho</td><td>Outperform</td><td>$365</td><td>$360</td><td>+38.0%</td></tr><tr><td>BofA</td><td>Buy</td><td>$385</td><td>$345</td><td>+32.3%</td></tr><tr><td>Morgan Stanley</td><td>Overweight</td><td>$385</td><td>$339</td><td>+30.0%</td></tr><tr><td>Needham</td><td>Buy</td><td>$390</td><td>$290</td><td>+11.2%</td></tr></tbody></table><figcaption>How Analysts Revised Lam Research's Price Targets &nbsp;</figcaption></figure></div><h2 class="st-heading-2">What Lam's Latest Earnings Revealed</h2>Lam's fiscal first-quarter revenue surged 22% sequentially to a record $8.22 billion, beating FiscalAI’s consensus estimate of $8.14 billion. Adjusted EPS came in at $2.20, topping expectations of $2.18.The company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lrcx-stock-record-profits-supply-snags-sales-hold-china-slowdown/cZxvH4rRBw4">reported</a> a non-GAAP gross margin of 52.4% and an operating margin of 40.2%. Management expects the global wafer fabrication equipment market to exceed $200 billion in calendar 2027, compared with an estimated mid-$150 billion range in 2026.<h2 class="st-heading-2">What Retail Thinks of LRCX Stock</h2>On Stocktwits, retail investors’ sentiment around LRCX stock remained in ‘extremely bullish’ territory amid extremely high message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_10_22_181148_2aa060e7c9.png" alt="Screenshot 2026-10-22 181148.png" width="809" height="422"><figcaption>LRCX stock retail sentiment on October 22, as of 8:30 a.m. ET | Source: Stocktwits</figcaption></figure>So far this year, LRCX stock has rallied nearly 41%. By comparison, the VanEck Semiconductor ETF (<a href="https://stocktwits.com/symbol/SMH">SMH</a>) and the&nbsp; State Street Technology Select Sector SPDR ETF (<a href="https://stocktwits.com/symbol/XLK">XLK</a>), which hold the stock, have rallied around 49% and 31%, respectively, over this period.See Also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meta-s-muse-ai-momentum-wins-over-analysts-but-140-b-spending-outlook-raises-funding-questions/cZxwI3ORBws">Meta's Muse AI Momentum Wins Over Analysts — But $140B Spending Outlook Raises Funding Questions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Lam Research Corp. booth at the Semicon Taiwan exhibition in Taipei, Taiwan, on Wednesday, Sept. 2, 2026. The exhibition runs through September 4. Photographer: Lam Yik Fei/Bloomberg via Getty Images

Lam Research Corp. (LRCX) shares tumbled more than 8% in Thursday's premarket trading as multiple firms lowered their price targets following the semiconductor equipment maker's latest earnings report,

LRCX Stock Sinks: Lam Research’s Supply Constraints May Be Capping Growth – Here’s What Analysts Say

The cuts followed better-than-expected fiscal first-quarter results, although analysts maintained positive ratings despite the company's December-quarter outlook offering limited upside to expectations.

VanEck Semiconductor ETF

Technology Select Sector SPDR Fund

Track LRCX stock price, charts, news and real-time market activity on Stocktwits. Join the LRCX message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Lam Research Corp stock.

LRCX Stock Price Today - Lam Research Corp News, Charts, Retail Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$200.44
Prev Close	$185.20
Open	$208.65
Dividend Yield	0.27%
50-Day Moving Average	$284.37
Beta	2.37
Avg. Volume	10.48M
PE Ratio	29.82

52-Week High	$438.50
52-Week Low	$135.50
Market Capitalization	$250.38B
EPS (Annual)	$5.76
Price to Book	18.00
Revenue Per Employee	$997,111.16

Feed

News

Sentiment

Earnings

Fundamentals

Info

LRCX Fundamentals